Skip to main content
Caplight Logo









NewBiologix

NewBiologix

Private
EpalingesHealthcare & Life Scienceshttps://newbiologix.com/

Last Round

Series A

May 11, 2023

Total Funding Raised

$50M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

NewBiologix is a biotechnology company that develops a DNA integration platform for the advanced engineering of cell lines used in gene and cell therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

engineered cell linesviral vector manufacturinggene therapyrAAV productionAAV manufacturingcell line developmentcell line engineeringstable cell linesbiomanufacturingprocess developmentCDMO servicesbioinformatics platformgenomic analysiscell therapyHEK293 cell linesnext-generation sequencingNGS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NewBiologix Comparables

Compare NewBiologix with similar companies based on industry and business-model similarity.

NewBiologix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
64x Bio
87%
Asimov
84%
Agathos Biologics
77%

NewBiologix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 11, 2023

Key People

Founding team and executive leadership

Tatjana Bauecker

CFO

Executive Team

Déborah Ley

Chief Operating Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 6, representing 24% of headcount.

  • Apr 17, 2026

    Monthly visitors grew 136% MoM, reaching 2K.

Recent news

Latest coverage and updates

  • is_developingSep 2, 2026

    NewBiologix SA is developing stable producer cell line on Sep 2nd '26.

  • is_developingSep 2, 2026

    NewBiologix SA is developing Xcell on Sep 4th '26.

NewBiologix Filings

Explore SEC and related filing metadata, where available.

NewBiologix filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about NewBiologix's valuation, stock price, and market status.

Is NewBiologix a public or private company?

NewBiologix is a private company.

What is the current stock price of NewBiologix?

NewBiologix is a private company with no public stock price. No recent secondary market data is available.

How much is NewBiologix worth (valuation)?

Valuation information for NewBiologix is not publicly available.

Can I buy NewBiologix stock?

NewBiologix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was NewBiologix's last funding round?

NewBiologix's most recent funding round was Series A on May 11, 2023.

Who are the main investors in NewBiologix?

Investor information for NewBiologix is not publicly disclosed.

Will NewBiologix IPO soon?

No public IPO plans have been announced for NewBiologix.

How can I track NewBiologix secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NewBiologix's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersEpalinges
Employee Range25
Year Founded2022
Last FundingMay 11, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?